Navigation Links
Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
Date:10/19/2011

ic option for physicians and their patients, should it be approved by the FDA at the end of October."

About Pacira

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL (bupivacaine liposome extended-release injectable suspension), the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postsurgical analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.

About EXPAREL™

EXPAREL (bupivacaine liposome extended-release injectable suspension) is Pacira's proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam®, both of which are currently used separately in FDA-approved products. Bupivacaine is a well-characterized anesthetic/analgesic that has an established safety profile with more than 20 years of use in the United States. Market data indicate that there is an unmet medical need for a longer-acting anesthetic/analgesic for postsurgical pain management. Several Phase 2 and Phase 3 clinical trials have been completed for EXPAREL and suggest statistically significant reduction of pain in soft tissue and orthopedic surgery i
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
2. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
3. Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
4. Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
5. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
6. Pacira Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
7. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
8. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
9. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
10. Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months
11. Pacira Pharmaceuticals, Inc. Appoints Two Life Sciences Industry Veterans to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "The Future of ... As they are in a desperate need ... and low cost, drug companies have been increasingly ... enhance their productivity while constantly streamlining their internal ...
(Date:6/3/2015)... 3, 2015  Varian Medical Systems (NYSE: VAR ), world ... cancer, is expanding in the Middle East ... Saudi Arabia . Varian Medical Systems Arabia, the ... was officially launched today at a ceremony attended by local ... "This move represents the next step in our commitment ...
(Date:6/3/2015)... June 02, 2015 Research and Markets ... the "2015 Strategies in the US Tumor ... Highlights of the Report Include ... tumor marker testing market. , Major issues ... as key economic, regulatory, demographic, social and technological ...
Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2United States Strategies in the Tumor Marker Testing Market 2015 2
... May 5, 2011 Novartis Pharmaceuticals Corporation ("Novartis") announced ... approved Afinitor® (everolimus) tablets for the treatment of progressive ... unresectable, locally advanced or metastatic disease(4). This marks the ... in the US in nearly 30 years(5). ...
... FRANCISCO, May 5, 2011 Cardiac Network, Inc. (Other OTC: ... a 1-for-750 reverse stock split (the "Reverse Stock Split"). The ... business and trading on May 6, 2011 (the "Effective Date"). ... changed from "CNWI" to "CNWID" for approximately 20 business days, ...
Cached Medicine Technology:Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 2Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 3Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 4Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 5Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 6Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 7Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 8Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 9Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 10Cardiac Network Announces Reverse Stock Split 2
(Date:6/3/2015)... On the heels of a report predicting ... ( click here to review news coverage about the ... has the talent to become a world-leading center of ... other biological data are collected and analyzed to help scientists ... the elements of a perfect storm for bioinformatics leadership,” said ...
(Date:6/3/2015)... Dr. Steven Reisman, a nationally recognized cardiologist ... http://www.newyorkcardiac.com ) located in NYC, announced today the expansion of ... In most cases, depending on the level of care a ... they will be seen by a cardiologist that same day. ... is to ensure that people who have an urgent need ...
(Date:6/3/2015)... 2015 Array Health , a ... announced that CEO Jonathan Rickert will present at ... June 4, 2015. The session will address the how ... traditional business models in health care, and why they ... Digital Transformation and the Health Care Enterprise: Driving ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... strategic partnership to expand online and mobile access ... Board Review and Maintenance of Certification (MOC) activities. ... will market VeoMed’s innovative courses to Decker’s extensive ... professionals interested in purchasing access to VeoMed’s premier ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 Justina ... Global Inspire Award at DIA’s upcoming Annual Meeting. DIA’s ... for their leadership, level of excellence, and commitment to ... will receive the Excellence in Service Award that recognizes ... service as a DIA volunteer and who has contributed ...
Breaking Medicine News(10 mins):Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3
... Eric Artz and team from the Institute of Tropical Medicine ... AIDS, in which they have said that the HIV virus ... is now more sensitive to anti-retroviral drugs compared to the ... the HIV samples collected in between 1986-89 with the samples ...
... disease may not require blood transfusion as a ... form of severe thalassaemia in many Asian// countries—can ... a research letter published online in the September ... the finding has important implications for supplies of ...
... single protein has helped bald mice to get fur on ... balding men., ,Catherine C. Thompson and colleagues at Johns ... known as Hairless, which encodes a protein that is essential ... with mutations in the Hairless gene, hair growth is initially ...
... ban the Environmental Protection Agency (EPA) from using human ... Lawmakers on Capitol Hill will soon decide whether to ... use of studies that expose participants to pesticides. In ... have their pesticides approved by the agency for marketing. ...
... some people vulnerable to suffer from the dreaded disease ... diagnose the risk//. ,According to the most complete ... the researchers from Vanderbilt University in Nashville, Tennessee at ... in San Diego, a cluster of genes on chromosome ...
... a limit to how tiny gadgets, devices and machines ... from an experiment performed by a University of Arizona// ... and assistant professor of physics Alexander D. Cronin. ... can come to a surface before the atoms' wavelengths ...
Cached Medicine News:Health News:US Senate Votes against Testing of Pesticide on Humans 2Health News:Nanotechnologists Specify Limitation For Devising Small Machines 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: